TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04626102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating Attitudes and Behaviours Group Program (Experimental Group Condition)
Description: The program has been developed by Clinical Psychologist Başak İnce and Psychiatrist Prof. Dr Başak Yücel. The session topics and contents of this program were based on the Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and 10-week online version of StudentBodies program designed by Saekow and her colleagues (2015). Program protocol was written based on Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and Fursland and her colleagues (2007)'s book titled Overcoming Disordered Eating.~This program aimed to inform participants about the causes and consequences of eating disorders, teach cognitive and behavioural techniques to change their unhealthy eating attitudes and behaviours, and provide support during their attitudinal and behavioural changes. Each week, participants were asked to complete homework activities which were related to topics covered in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Disorders and Body Dissatisfaction: A Group Work (Active Control Group Condition)
Description: This single-session group program was designed as an active control group for the purpose of this study. The content of the program was prepared based on Stice and his colleagues (2013)'s four - sessions Body Project eating disorders prevention program. This single-session program aimed to inform participants about causes and consequences of eating disorders, and discuss thin ideal messages created by media and the negative impact of these messages on women's body images, and address possible ways of countering these messages. Detailed information regarding the covered topics and video presentations in the group session is provided below.
Study: NCT02025790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per Oral Endoscopic Myotomy (POEM)
Description: * Mucosal incision - After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 12 cm proximal to the gastroesophageal junction (GEJ).~* Submucosal tunneling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~* Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~* Long endoscopic myotomy is performed 10 cm proximal to GEJ extending~* Closure of mucosal entry: the mucosal incision is closed using hemostatic clips

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Dilatation
Description: Pneumatic dilatation using a Rigiflex balloon up to 35 mm at 8 psi for 1 minute.
Study: NCT04946604

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ashtangayoga
Description: This is an active and intense type of yoga, focused on physical activity and breath control
Study: NCT04034628

Intervention type: DEVICE
Intervention: Peritoneal Catheter Insertion - Percutaneous
Description: Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure

Intervention type: DEVICE
Intervention: Peritoneal Catheter Insertion - Percutaneous
Description: Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
Study: NCT02990689

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trifocal Intraocular Lens
Description: bifocal intraocular lens (IOL)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bifocal Intraocular Lens
Description: trifocal intraocular lens (IOL)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Addition Bifocal Intraocular Lens
Description: low near addition intraocular lens (IOL)
Study: NCT04055974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be a Mom
Description: The Be a Mom program is a web-based self-guided cognitive-behavioral intervention targeting postpartum women. It consists of 5 weekly modules, each targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
Study: NCT00477984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcohol
Description: alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
Study: NCT02461264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single red blood packed cells Transfusion
Study: NCT01501357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified toothbrush with multilevel filaments
Description: After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.
Study: NCT02829632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Sessions
Description: Participants will receive a 3-session behavioral lifestyle program for a healthful lifestyle and weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Participants will receive an one-time how to self-monitor using the smartphone session.
Study: NCT01501357

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cross toothbrushing
Description: Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique
Study: NCT04183348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Protocol n°1 first at Visit 1, then, Training Protocol n°2 at Visit 2
Description: During Protocol 1 (visit 1), participants of Group A will perform auditory spatial localization tasks with sensory feedback and during Protocol 2 (visit 2), they will perform auditory tasks without any notion of spatial localization. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Protocol n°2 first at Visit 1, then, Training Protocol n°1 at Visit 2
Description: During Protocol 2 (visit 1), participants of Group B will perform auditory tasks without any notion of spatial localization and during Protocol 1 (visit 2), they will perform auditory spatial localization tasks with sensory feedback. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol.
Study: NCT00454116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: once daily oral tablet two doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: once daily oral tablet two doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFIRI
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Intravenous infusion
Study: NCT03186339

Intervention type: PROCEDURE
Intervention: TAVI
Description: transfemoral transcatheter aortic valve implantation

Intervention type: PROCEDURE
Intervention: SAVR
Description: isolated surgical valve replacement

Intervention type: OTHER
Intervention: MM
Description: management of aortic stenosis by medical treatment only
Study: NCT02431325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04167527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device
Description: Treatment initiation is defined as the date and time of arterial puncture. Femoral artery puncture will occur within 45 minutes of randomization and no longer than 90 minutes after the completion of the qualifying imaging. It must occur before 8 hours since the subject was last known well.The initial procedure will be performed using only the EmboTrap II Retriever for the first two passes, and a third pass is encouraged. Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two hours of arterial access.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Initial medical management (iMM)
Description: Patients will receive standard medical therapy based on current AHA guidelines. For patients who are treated with intravenous tissue plasminogen activator (rtPA), the sites' post-rtPA protocol will be followed. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location.
Study: NCT02829632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Participants will receive an one-time how to self-monitor using the smartphone session.
Study: NCT00611221

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Massage therapy by an RMT during labour

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Massage by anyone else, eg. husband, nurse, doula
Study: NCT05594108

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasonography
Description: transabdominal ultrasonography
Study: NCT03077763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite
Study: NCT01644942

Intervention type: OTHER
Group type: OTHER
Intervention: Lipid accumulation analysis
Description: The lipid accumulation will be assessed with muscular biopsies.

Intervention type: OTHER
Group type: OTHER
Intervention: Lipid accumulation analysis
Description: The lipid accumulation will be assessed with muscular biopsies.
Study: NCT02420223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study: NCT00884052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose levetiracetam
Description: 20 mg/kg loading dose; 5 mg/kg daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose levetiracetam
Description: 40 mg/kg IV load; 10 mg/kg/day maintenance
Study: NCT04625894

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: To irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate. Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy). Sequence of irradiation for multiple metastases will be at the discretion of the investigators based on their experience.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab for injection (200 mg, iv), D1, Q2W, 14-day cycle
Description: Administration of Carrelizumab will be started within one week upon SABR completion, and will be continued for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
Study: NCT01028833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power mobility
Description: Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
Study: NCT01262612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: immediate cediranib
Description: cediranib 30 mg on day one; Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Start cediranib after 28 days Best Supportive Care
Description: patients in this group will start with cediranib after one month best supportive care. Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken.
Study: NCT02104999

Intervention type: DEVICE
Group type: OTHER
Intervention: Point-of-care test for CRP
Description: Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
Study: NCT01128569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate
Description: FF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/Vilanterol (VI; GW642444M)
Description: FF/VI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Inhaler
Study: NCT00894387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg and Aliskiren 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04239248

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tasty&Healthy intervention group
Description: patients will receive dietary advice to exclude pro-inflammatory dietary components based on the book Tasty\&Healthy.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tasty&Healthy intervention group
Description: patients will receive dietary advice to exclude pro-inflammatory dietary components based on the book Tasty\&Healthy.
Study: NCT02461264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two packed red blood cells Transfusion
Study: NCT04239248

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EEN intervention group
Description: Oral exclusive feeding of formulated food (EEN), using Modulen formula only, for 8 weeks in amount based on the Daily Recommendations Intake. Those not tolerating oral EEN can receive EEN via a nasogastric tube.
Study: NCT01603017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI therapy
Description: 5 treatments with magnetic field delivered to knee (n=50)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI therapy (off)
Description: 5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
Study: NCT01641484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local control at 19.8Gy
Description: Day 14, full body TEP and pelvis MRI
Study: NCT04008914

Intervention type: OTHER
Intervention: retrospective observation
Description: Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.

Intervention type: OTHER
Intervention: retrospective observation
Description: Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.
Study: NCT02734329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic partial nephrectomy
Description: renal artery will be clamped during surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)
Study: NCT00795028

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care for people after hip fracture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care + exercise intervention
Study: NCT02115321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: EBR was supplied as 50 mg tablets and was taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: EBR was supplied as 50 mg tablets and was taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: EBR was supplied as 50 mg tablets and was taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: EBR was supplied as 50 mg tablets and was taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5172A
Description: MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
Study: NCT02313363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: patient-centered smartphone-based diabetes care system
Description: patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.
Study: NCT00378716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Study: NCT02115321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5172A
Description: MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
Study: NCT05918614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral
Study: NCT04701879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spine decompression with core stability exercises
Description: * 50 minutes per session~* Decompression with core stability on alternate days for 8 visits.
Study: NCT02493764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relebactam
Description: Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilastatin
Description: Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin
Description: Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
Study: NCT04701879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spine decompression
Description: 40 minutes per session~-Decompression therapy on alternate days for 8 visits.
Study: NCT03264261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic training
Description: robotic training, 3 times/week for 6 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill training
Description: treadmill training only, 3 times/week for 6 weeks
Study: NCT02290067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood glucose monitoring system (Omnitest 3)
Study: NCT03444870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the respective arm.
Study: NCT00657124

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aminolevan EN
Description: The present study used carbohydrate and BCAA-enriched soft-powder nutrient-mixture for preoperative supplementation. Supplementation with Aminolevan EN (100 g per day) started at two weeks prior to the surgery under the careful monitoring of compliance.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo